Minnesota is currently home to 2055 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
NCT06174805
Recruiting
To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Gastric Outlet Obstruction
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by observation for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
BLOODSAFE Ghana- Iron and Nutritional Counselling Strategy
NCT06101238
Recruiting
A randomized trial will compare 6-months of low-dose (65mg elemental iron daily) among prospective blood donors who are deferred for low haemoglobin but have passed all of the other pre-screening requirements for blood donation to a group of donors who were deferred from donating and receive the current standard of care (nutrition counseling only). An automated full blood count (FBC) will also be done to identify any safety concerns. The randomized trial will evaluate effectiveness with the prim... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Blood Donation
Register for Updates
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
NCT06096844
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
04/15/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/15/2025
Locations: M Health Fairview University of Minnesota Medical Center - CSC - Center for Lung Science and Health, Minneapolis, Minnesota
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493
Recruiting
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
Register for Updates
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic - Rochester, 200 First Street, SW, 55905, Rochester, Minnesota
Conditions: Post-Bariatric Hypoglycemia
Register for Updates
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
NCT05904080
Recruiting
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8, Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Register for Updates
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
NCT05900050
Recruiting
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and failures in the presence of liver cirrhosis (Acute-on-Chronic Liver Failure, ACLF) and accumulation of fluid in the abdominal cavity (ascites)
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Acute-On-Chronic Liver Failure, Ascites
Register for Updates
Remotely Delivered Cognitive Multisensory Rehabilitation for Sensory and Motor Recovery After Spinal Cord Injury
NCT05870189
Recruiting
So far, therapies have limited success in functional recovery in adults with chronic SCI. By introducing remote cognitive multisensory rehabilitation (CMR), which has shown significant functional improvements due to neurological recovery when delivered in-person, transformative results that (i) provide a potentially effective new therapy within the healthcare system, accessible to more patients, and (ii) demonstrate brain function changes alongside improved function in chronic SCI are anticipate... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Spinal Cord Injuries, Spinal Cord Diseases
Register for Updates
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Register for Updates